

for the five mouse tumor types reported on averaged only -7.1! Three of these types (sarcoma 37S, tar carcinoma 2146, and spindle-cell tar tumor 173) had an average  $Q_{O_2}$  of -5.6, compared with -16.6 for the same tumor strains as measured by Crabtree and used by Weinhouse. Thus, even the *unadjusted* average tumor  $Q_{O_2}$  value employed by Weinhouse (-11.8) is, as the result of unwarranted bias in selection and incomplete utilization of available data, much too high.

11. Weinhouse's confusion is infectious, although mainly among investigators who do not themselves perform laboratory experiments on cancer metabolism. One may read, for example, "We hear about THE metabolism of THE cancer cell. Unfortunately, no such phenomenon has been established. . . . As Dr. Weinhouse said at the opening of the symposium, the critical difference between metabolism in malignant tissues and in normal tissues does not appear to reside in the major ways in which they handle carbohydrate metabolism." [*Antimetabolites and Cancer* (AAAS, Washington, D.C., 1955, pp. 305, 308)]. Such statements could scarcely be more incorrect or uninformed. They set the clock back and encourage the empirical approach to the problem of cancer by a sheer and vicarious denial of available fundamental information.
12. G. N. Lewis, *The Anatomy of Science* (Yale Univ. Press, New Haven, Conn., 1926), p. 171.
13. In paragraphs 4, 5, and 6 of his note in this issue of *Science*, Weinhouse asks or raises several questions that have been asked, discussed, and answered many times in the literature of cancer.
14. The mechanism of the cancer respiratory impairment may indeed often involve lowered content of a particular respiratory enzyme, but this is not a necessary general requirement, since internal cellular arrangement and chemical or structural restraint of other correlated enzymes are, as in so many living phenomena, often of more decisive importance. Thus, certain ascites cancer cells have been found [B. Chance and L. N. Castor, *Science* 116, 200 (1952)] to have unusually high contents of cytochrome *c*; but even in such ascites cells, the paraphenylenediamine and succinate oxidative responses are characteristically low or zero (1, p. 314); this is clearly indicative of respiratory restraint in spite of abnormally high absolute content of cytochrome *c* (compare 4, pp. 295-6). Oxidation-reduction potential restraints may well be involved here, as well as low contents of cytochrome *b* or DPNH demonstrated.
15. I. Newton, *Opticks* (W. and J. Innys, London, ed. 2, 1718), pp. 344, 351.
16. Presented orally at the 1956 meeting of American Association for Cancer Research. [*Proc.* 2, 98 (Natl. Inst. of Health Information Release, 13 Apr.)].
17. A description of these quantitative potentialities and other qualitative aspects is in preparation.

2 July 1956

## On the Biosynthesis of the Porphyrinlike Moiety of Vitamin B<sub>12</sub>

The investigations performed during the past decade have elucidated many of the intimate biosynthetic steps by which the cell elaborates the porphyrin molecule. It has been found that "active" succinate (1) and glycine (2) are the sole precursors of the porphyrin compounds in all biological systems studied. The glycine and succinate condense to form  $\alpha$ -amino- $\beta$ -ketoacid. This  $\beta$ -keto acid on decarboxylation yields  $\delta$ -aminolevulinic acid (3). Condensation of 2 mole of the aminoketone results in the formation of the precursor monopyrrole, porphobilinogen (4). Four mole of this

pyrrole then condenses to form a porphyrin, and modification of the side chains in the  $\beta$ -positions gives rise to a particular porphyrin.

The chemical work of the Merck group (5) and of the English workers (6) and the x-ray studies of Hodgkin *et al.* (7) have culminated recently in the proposal of a very probable structure of vitamin B<sub>12</sub> which contains a porphyrinlike structure (6, 7). Although this latter component of the vitamin differs somewhat in structure from that of porphyrins (that is, the vitamin molecule contains one pyrrolidine and three pyrroline rings, a methyl group on two of the bridge-carbon atoms, four extra methyl groups in the  $\beta$ -positions of the rings, and an  $\alpha$ -methyl group instead of a bridge-carbon atom), there are sufficient similarities to lead to the suspicion that the basic mechanism of synthesis of this part of the vitamin is similar to that known for porphyrins. It would seem possible that the porphyrinlike moiety of the vitamin is synthesized by the mechanism known for pyrrole and porphyrin synthesis and that the modified structure is subsequently methylated in the afore-mentioned positions to form the final product. This conclusion, of methylation subsequent to ring formation from  $\delta$ -aminolevulinic acid (6), is supported by structural considerations. If a methylated derivative of  $\delta$ -aminolevulinic acid were the precursor, one would expect that the extra methyl groups would be on only those  $\beta$ -positions that bear acetic acid side chains. However, this is the case with only rings A and B; in ring D the methyl group is attached to the carbon atom that bears the propionic acid group.

In order to check this hypothesis, we have carried out a microbiological synthesis of vitamin B<sub>12</sub> in the presence of 125 mg of  $\delta$ -aminolevulinic acid-1,4-C<sup>14</sup> having a molar activity (1) of  $8.3 \times 10^5$  count/min for each active carbon. The culture was agitated in a medium containing the following nutrients, in addition to the  $\delta$ -aminolevulinic acid: sucrose, 8.75 g; L-glutamic acid, 2.5 g; (NH<sub>4</sub>)<sub>2</sub>HPO<sub>4</sub>, 0.5 g; Na<sub>2</sub>SO<sub>4</sub>, 0.5 g; KCl, 0.2 g; MgSO<sub>4</sub> · 7H<sub>2</sub>O, 0.125 g; MnSO<sub>4</sub> · 4H<sub>2</sub>O, 0.05 g; FeSO<sub>4</sub> · 7H<sub>2</sub>O, 0.005 g; ZnSO<sub>4</sub> · 7H<sub>2</sub>O, 0.005 g; and Co(NO<sub>3</sub>)<sub>2</sub> · 6H<sub>2</sub>O, 0.01 g. Under these fermentation conditions, the culture produced 0.163 mg of vitamin B<sub>12</sub>. After the addition of 10.1 mg of nonradioactive B<sub>12</sub>, 6.294 mg of B<sub>12</sub> was isolated. The molar activity of the undiluted B<sub>12</sub> was  $30 \times 10^5$  count/min. Therefore, in the unlikely possibility that endogenous synthesis of aminoketone be disregarded, at least four carbon atoms of the vitamin must have contained C<sup>14</sup>.

On the reasonable assumption, based on previous studies on porphyrin formation, that 2 mole of aminoketone is utilized for each ring, one can postulate

that 15 labeled carbon atoms (16 minus the carboxyl lost from ring C) of the porphyrinlike structure of the vitamin were derived from our labeled substrate. On this basis the molar activity of each of these 15 carbon atoms would be  $2 \times 10^5$  count/min. This represents a mere four-fold dilution of the radioactive carbon atoms of the labeled substrate in the course of the synthesis of the vitamin. It may therefore justifiably be concluded that the porphyrinlike structure of vitamin B<sub>12</sub> is synthesized from  $\delta$ -aminolevulinic acid, as are the porphyrins, and that the mechanism of synthesis of the ring system in the vitamin is similar to that of the porphyrins.

We are presently engaged in degrading the labeled vitamin in order to isolate those carbon atoms which we predict should contain all the radioactivity.

DAVID SHEMIN\*

JOHN W. CORCORAN†

Department of Biochemistry, College of Physicians and Surgeons, Columbia University, New York, New York

CHARLES ROSENBLUM

IAN M. MILLER

Merck, Sharp, and Dohme Research Laboratory, Merck and Company, Rahway, New Jersey

## References and Notes

1. D. Shemin, and J. Wittenberg, *J. Biol. Chem.* 192, 315 (1951); D. Shemin and S. Kumin, *ibid.* 198, 827 (1952).
2. D. Shemin and D. Rittenberg, *ibid.* 166, 621, 627 (1946).
3. D. Shemin and C. S. Russell, *J. Am. Chem. Soc.* 75, 4873 (1953).
4. K. D. Gibson, A. Neuberger, J. J. Scott, *Biochem. J. (London)* 58, XLI (1954); R. Schmid and D. Shemin, *J. Am. Chem. Soc.* 77, 506 (1955).
5. F. A. Kuehl, Jr., C. H. Shunk, K. Folkers, *J. Am. Chem. Soc.* 77, 251 (1955).
6. R. Bonnett, *et al.*, *Nature* 176, 328 (1955).
7. D. C. Hodgkin, *et al.*, *ibid.* 176, 325 (1955).
- \* Supported in this work by grants from the National Institutes of Health, U.S. Public Health Service (A-1101, C7); from the American Cancer Society, on the recommendation of the Committee on Growth of the National Research Council; from the Rockefeller Foundation; and from the Williams-Waterman Fund.
- † Aided by a research fellowship from the American Heart Association.

28 May 1956

## Cell-Wall Mannan-Protein of Baker's Yeast

In isolated cell walls of baker's yeast, Northcote and Horne (1) demonstrated the presence of two polysaccharides, an outer glucan envelope and an inner mannan component. Associated with the latter was nitrogenous material. This material was assumed to be protein on the basis of the detection (by chromatography) of amino acids in the products of its partial hydrolysis. The glucan was subsequently shown (2) to comprise about 10 percent, and mannan 15 to 17 percent, of the dry weight of baker's yeast. The wall constituents accounted